Investors
Investing in High Potential Markets with Significant Unmet Needs
Bexion Media
Press Release
Bexion Pharmaceuticals, Inc. Announces Poster Presentation on BXQ-350 at the American Association for Cancer Research (AACR) Annual Meeting 2024
COVINGTON, Ky., April 10, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company presented a poster on BXQ-350 during the American Association for Cancer Research (AACR) Annual Meeting 2024 which took place April 5-10, 2024, in San Diego, CA. Poster details are included below. Poster Details: Abstract Title: BXQ-350: A novel biologic that [...]
Cincinnati Enquirer: 8 Cincinnati biotech companies with big steps to watch in 2020
Excerpt: Cincinnati has become a nurturing place for bright ideas in biotechnology, and 2020 could bring big advancements. The Cincinnati USA Regional Chamber of Commerce estimates the industry contributes more than $3 billion to the area economy. Nearly 800 locations employ more than 13,000 workers who are making average salaries of about $100,000 a year. In alphabetical order, here are eight Cincinnati biotechs aiming for milestones in 2020. Bexion Pharmaceuticals [...]
Investment Pillars
Bexion is well positioned to achieve our ambitious targets and change the treatment landscape in Oncology and CIPN.
The BXQ-350 clinical development plan is one that really excites me. The Bexion team has very intentionally chosen metastatic colorectal cancer and peripheral neuropathy based on the profile of it’s lead compound BXQ-350, and is rapidly progressing towards later stage clinical trials and commercialization.
Shabnam Kazmi, M.B.A.
Commercialization Advisor
Bexion has made significant advances in Manufacturing and has produced sufficient drug to support Phase two studies. This represents a real advantage to investors because we have derisked manufacturing and have set the hurdles higher for any competition.
Michael Gazda, Ph.D.
Chemistry, Manufacturing, and Controls